NCT03962101View on ClinicalTrials.gov

Safety Trial of OPC-61815 Injection in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake

PHASE3CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

June 17, 2019

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Congestive Heart Failure
Interventions
DRUG

OPC-61815 injection

Intravenous administration of OPC-61815 at 8 mg or 16 mg once daily for a maximum of 5 days. Starting with 8mg, increase the dose to 16mg on Day 2 or Day 3, according to the dose escalation criteria.

Trial Locations (1)

Unknown

Gifu Prefectural General Medical Center, Gifu

Sponsors
All Listed Sponsors
lead

Otsuka Pharmaceutical Co., Ltd.

INDUSTRY